Raymond James & Associates’s Citius Pharmaceuticals CTXR Stock Holding History

Raymond James & Associates’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-463	Closed	-$23K	–	4169
2021 Q3	$23K	Buy	463 +3	+0.7%	+$151	﹤0.01%	3994
2021 Q2	$40K	Buy	+460	New	+$27.6K	﹤0.01%	3932
2020 Q2	–	Sell	-480	Closed	-$7K	–	3541
2020 Q1	$7K	Hold	480	–	–	﹤0.01%	3458
2019 Q4	$12K	Hold	480	–	–	﹤0.01%	3629
2019 Q3	$9K	Hold	480	–	–	﹤0.01%	3568
2019 Q2	$12K	Hold	480	–	–	﹤0.01%	3577
2019 Q1	$17K	Hold	480	–	–	﹤0.01%	3538
2018 Q4	$12K	Hold	480	–	–	﹤0.01%	3465
2018 Q3	$21K	Hold	480	–	–	﹤0.01%	3541
2018 Q2	$28K	Hold	480	–	–	﹤0.01%	3479
2018 Q1	$37K	Hold	480	–	–	﹤0.01%	3349
2017 Q4	$46K	Buy	+480	New	+$48.1K	﹤0.01%	3289

Other funds holding CTXR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Raymond James & Associates's CTXR Position: Q4 2021 in Review

Raymond James & Associates sold out of Citius Pharmaceuticals (CTXR) in Q4 2021, closing a stake of 463 shares — an estimated $23K sold.

Raymond James & Associates first reported a position in CTXR in Q4 2017 and held it in 12 quarters. The position peaked at $46K in Q4 2017. 76 funds tracked by Wall St. Rank hold CTXR as of Q4 2021.

Raymond James & Associates reported no remaining Citius Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Raymond James & Associates sold 463 Citius Pharmaceuticals shares in Q4 2021, an estimated $23K.
Raymond James & Associates first reported a position in Citius Pharmaceuticals in Q4 2017 and held it in 12 quarters.
Raymond James & Associates's Citius Pharmaceuticals position peaked at $46K in Q4 2017.
76 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2021.

Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.